EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

First‐Line Tocilizumab Monotherapy for Juvenile Systemic Sclerosis With Interstitial Lung Disease: A Case Report

Tadafumi Yokoyama iD, Natsumi Inoue iD, Satoshi Watanabe, Takashi Matsushita iD, Taizo Wada iD

Case Reports in Rheumatology · 2026-01 · 2026 (1)

DOI: 10.1155/crrh/2914024 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Rheumatology, online erschienen am 12.08.2026. Verfasst von Tadafumi Yokoyama und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Kanazawa University Hospital, Takara-Machi 13-1, Kanazawa Ishikawa, 920-8640, Japan, kanazawa-u.ac.jp. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic sclerosis, a rare autoimmune disease in children, frequently presents with aggressive clinical features and high risk of interstitial lung disease. Tocilizumab, an anti–interleukin‐6 receptor monoclonal antibody, has exhibited efficacy in adult systemic sclerosis with interstitial lung disease; however, evidence in pediatric cases remains extremely limited. We report a 12‐year‐old Japanese girl who developed early‐stage juvenile systemic sclerosis with interstitial lung disease, presenting with Raynaud’s phenomenon, puffy fingers, positive anti–topoisomerase I antibody, reduced pulmonary function, and ground‐glass opacities on high‐resolution computed tomography. Consequently, tocilizumab monotherapy was initiated. During a follow‐up period of over 3 years, her pulmonary function remained stable, and high‐resolution computed tomography showed partial resolution of interstitial changes. No significant adverse events, such as severe infections or cytopenias, were observed. Early tocilizumab initiation may represent a potential therapeutic option for juvenile systemic sclerosis with interstitial lung disease. However, further studies are warranted to validate its role and optimize treatment guidelines for this rare but severe condition.

Schlagwörter

Stichwörter der Autor:innen

early-stageinterstitial lung diseasejuvenile systemic sclerosispediatrictocilizumab

Autor:innen und Institutionen

  • Department of Pediatrics, Kanazawa University Hospital, Takara-Machi 13-1, Kanazawa Ishikawa, 920-8640, Japan, kanazawa-u.ac.jp.
  • Respiratory Medicine, Kanazawa University Hospital, Takara-Machi 13-1, Kanazawa Ishikawa, 920-8640, Japan, kanazawa-u.ac.jp.
  • Department of Dermatology, Kanazawa University Hospital, Takara-Machi 13-1, Kanazawa Ishikawa, 920-8640, Japan, kanazawa-u.ac.jp.

ORCID-Profile: Tadafumi Yokoyama, Natsumi Inoue, Takashi Matsushita, Taizo Wada

Zitieren

APA

Yokoyama, T., Inoue, N., Watanabe, S., Matsushita, T., & Wada, T. (2026). First‐Line Tocilizumab Monotherapy for Juvenile Systemic Sclerosis With Interstitial Lung Disease: A Case Report. Case Reports in Rheumatology, 2026(1). https://doi.org/10.1155/crrh/2914024

Vancouver

Yokoyama T, Inoue N, Watanabe S, Matsushita T, Wada T. First‐Line Tocilizumab Monotherapy for Juvenile Systemic Sclerosis With Interstitial Lung Disease: A Case Report. Case Reports in Rheumatology. 2026;2026(1). doi:10.1155/crrh/2914024

BibTeX
@article{Yokoyama2026,
  author = {Yokoyama, Tadafumi and Inoue, Natsumi and Watanabe, Satoshi and Matsushita, Takashi and Wada, Taizo},
  title = {First‐Line Tocilizumab Monotherapy for Juvenile Systemic Sclerosis With Interstitial Lung Disease: A Case Report},
  journal = {Case Reports in Rheumatology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crrh/2914024}
}
Kostenlos starten →